Skip to main content
Fig. 2 | Biomarker Research

Fig. 2

From: Sitravatinib as a potent FLT3 inhibitor can overcome gilteritinib resistance in acute myeloid leukemia

Fig. 2

The interaction of sitravatinib and FLT3. A Overview of the docking results of sitravatinib with FLT3 (Protein Data Bank: 6JQR) from two orthogonal views. B Close-up of the sitravatinib-FLT3 model highlighted the detailed binding sites of sitravatinib with FLT3. The atoms of sitravatinib are colored by the type of element (grey: carbon; blue: nitrogen; red: oxygen; cyan, fluorine; yellow: sulfur). For clarity, the hydrogen atoms are omitted. Molecular interactions are shown as red lines. C BaF3-FLT3-ITD cells were treated with sitravatinib (30 μM/mL) or DMSO for 1 h, temperatures between 38–58.2 °C were defined to perform the test. Quantification was made using western blot to determine the melting curve. Data are mean ± standard error from three independent experiments. D BaF3-FLT3-ITD cells were treated with sitravatinib from 0 to 1000 nM for 30 min and then heated at 51.7 °C for 3 min. Protein quantification was made using western blot and the best fit of the data was monitored. Data are mean ± standard error from three independent experiments

Back to article page